HU216194B - Eljárás hatóanyagként N-(4-trifluor-metil-fenil)-karboxamid-származékokat tartalmazó pszoriázis kezelésére alkalmas gyógyszerkészítmények előállítására - Google Patents

Eljárás hatóanyagként N-(4-trifluor-metil-fenil)-karboxamid-származékokat tartalmazó pszoriázis kezelésére alkalmas gyógyszerkészítmények előállítására Download PDF

Info

Publication number
HU216194B
HU216194B HU9400908A HU9400908A HU216194B HU 216194 B HU216194 B HU 216194B HU 9400908 A HU9400908 A HU 9400908A HU 9400908 A HU9400908 A HU 9400908A HU 216194 B HU216194 B HU 216194B
Authority
HU
Hungary
Prior art keywords
psoriasis
compound
formula
treatment
preparation
Prior art date
Application number
HU9400908A
Other languages
English (en)
Hungarian (hu)
Other versions
HUT70757A (en
HU9400908D0 (en
Inventor
Robert Ryder Bartlett
Ellen Smith Kurtz
Klaus Ulrich Weithmann
Original Assignee
Hoechst Ag.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21915403&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HU216194(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoechst Ag. filed Critical Hoechst Ag.
Publication of HU9400908D0 publication Critical patent/HU9400908D0/hu
Publication of HUT70757A publication Critical patent/HUT70757A/hu
Publication of HU216194B publication Critical patent/HU216194B/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physiology (AREA)
  • Pulmonology (AREA)
  • Nutrition Science (AREA)
  • Immunology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pyridine Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
HU9400908A 1993-03-31 1994-03-30 Eljárás hatóanyagként N-(4-trifluor-metil-fenil)-karboxamid-származékokat tartalmazó pszoriázis kezelésére alkalmas gyógyszerkészítmények előállítására HU216194B (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US4122393A 1993-03-31 1993-03-31

Publications (3)

Publication Number Publication Date
HU9400908D0 HU9400908D0 (en) 1994-06-28
HUT70757A HUT70757A (en) 1995-10-30
HU216194B true HU216194B (hu) 1999-05-28

Family

ID=21915403

Family Applications (1)

Application Number Title Priority Date Filing Date
HU9400908A HU216194B (hu) 1993-03-31 1994-03-30 Eljárás hatóanyagként N-(4-trifluor-metil-fenil)-karboxamid-származékokat tartalmazó pszoriázis kezelésére alkalmas gyógyszerkészítmények előállítására

Country Status (17)

Country Link
US (1) US5504084A (fi)
EP (1) EP0617959B1 (fi)
JP (1) JP2930281B2 (fi)
KR (1) KR100310665B1 (fi)
AT (1) ATE183088T1 (fi)
AU (1) AU670491B2 (fi)
CA (1) CA2120319C (fi)
CY (1) CY2207B1 (fi)
DE (1) DE69419954T2 (fi)
DK (1) DK0617959T3 (fi)
ES (1) ES2135500T3 (fi)
GR (1) GR3031264T3 (fi)
HU (1) HU216194B (fi)
IL (1) IL109151A (fi)
RU (1) RU2151597C1 (fi)
TW (1) TW314467B (fi)
ZA (1) ZA942257B (fi)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0787491B1 (en) * 1994-10-17 2000-07-26 Aventis Pharma Ltd. Preventive and remedy for type i allergic diseases
DE19547648A1 (de) * 1995-12-20 1997-06-26 Hoechst Ag Zubereitung, enthaltend High Density Lipoproteine und Crotonsäureamidderivate
US6011051A (en) * 1996-07-31 2000-01-04 Hoechst Aktiengesellschaft Use of isoxazole and crotonamide derivatives for the modulation of apoptosis
EP0987256B1 (de) 1997-08-08 2001-10-17 Aventis Pharma Deutschland GmbH Kristallform von N-(4-Trifluormethylphenyl)-5-methylisoxazol-4-carbonsäureamid
SI1381356T1 (sl) 2001-04-05 2008-12-31 Aventis Pharma Inc Uporaba (Z)-2-ciano-3-hidroksi-but-2-enojska kislina-(4'-trifluorometilfenil)-amida za zdravljenje multiple skleroze
US20050158371A1 (en) * 2002-02-12 2005-07-21 Sumitomo Pharmaceuticals Co., Ltd. Novel external agent
JPWO2005011669A1 (ja) * 2003-08-05 2006-09-14 大日本住友製薬株式会社 経皮投与用医薬組成物
US20110104186A1 (en) 2004-06-24 2011-05-05 Nicholas Valiante Small molecule immunopotentiators and assays for their detection
JPWO2006082834A1 (ja) * 2005-02-02 2008-06-26 興和株式会社 ケラチノサイト増殖に起因する疾患の予防・治療剤

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL186239B (nl) * 1975-06-05 Hoechst Ag Werkwijze voor de bereiding van een geneesmiddel met antiflogistische en/of analgetische werking, alsmede werkwijze voor de bereiding van een 2-hydroxyethylideencyaanazijnzuuranilide geschikt voor toepassing bij deze werkwijze.
DE2854439A1 (de) * 1978-12-16 1980-07-03 Hoechst Ag Ein isoxazolderivat, verfahren zu seiner herstellung, diese verbindung enthaltende mittel und verwendung
DE3035670A1 (de) * 1980-09-22 1982-04-29 Siemens AG, 1000 Berlin und 8000 München Vorrichtung zur infusion von fluessigkeiten in den menschlichen oder tierischen koerper
DE3534440A1 (de) * 1985-09-27 1987-04-02 Hoechst Ag Arzneimittel gegen chronische graft-versus-host-krankheiten sowie gegen autoimmunerkrankungen, insbesondere systemischen lupus erythematodes
US5268382A (en) * 1985-09-27 1993-12-07 Hoechst Aktiengesellschaft Medicaments to combat autoimmune diseases, in particular systemic lupus erythematosus
GB8619432D0 (en) * 1986-08-08 1986-09-17 Lilly Industries Ltd Pharmaceutical compounds
DE3927257A1 (de) * 1989-08-18 1991-02-21 Hoechst Ag Verfahren zur herstellung eines polyolefins
DD297328A5 (de) * 1989-08-18 1992-01-09 �������@���������k���Kk�� 5-methyl-isoxalol-4-carbonsaeureanilide und 2 hydroxyethyliden-cyanoessigsaeureanilide zur behandlung von augenerkrankungen
US5001124A (en) * 1990-02-02 1991-03-19 Syntex (U.S.A.) Inc. 4-isoxazolecarboxamide derivatives
EP0527736B1 (de) * 1990-05-18 1997-04-16 Hoechst Aktiengesellschaft Isoxazol-4-carbonsäureamide und hydroxyalkyliden-cyanessigsäureamide, diese verbindungen enthaltende arzneimittel und deren verwendung
IL99811A (en) * 1990-10-30 1996-03-31 Roussel Uclaf 3-Cycloalkyl-propanamides, tautomeric forms of these, their salts, method of preparation, use as drugs and preparations containing them
DE4227594A1 (de) * 1992-08-20 1994-02-24 Wacker Chemie Gmbh Synthetische Alumosilikate und ihre Verwendung als heterogene Äquilibrierungskatalysatoren

Also Published As

Publication number Publication date
HUT70757A (en) 1995-10-30
ES2135500T3 (es) 1999-11-01
AU5915794A (en) 1994-10-06
TW314467B (fi) 1997-09-01
RU2151597C1 (ru) 2000-06-27
JPH06329538A (ja) 1994-11-29
EP0617959A1 (en) 1994-10-05
KR940021060A (ko) 1994-10-17
GR3031264T3 (en) 1999-12-31
AU670491C (en) 1994-10-06
DE69419954T2 (de) 2000-04-13
HU9400908D0 (en) 1994-06-28
IL109151A0 (en) 1994-06-24
JP2930281B2 (ja) 1999-08-03
CA2120319A1 (en) 1994-10-01
CA2120319C (en) 2009-01-06
EP0617959B1 (en) 1999-08-11
ZA942257B (en) 1994-11-16
DE69419954D1 (de) 1999-09-16
IL109151A (en) 1998-12-27
ATE183088T1 (de) 1999-08-15
DK0617959T3 (da) 2000-01-24
KR100310665B1 (ko) 2001-12-28
US5504084A (en) 1996-04-02
AU670491B2 (en) 1996-07-18
CY2207B1 (en) 2002-11-08

Similar Documents

Publication Publication Date Title
US5519042A (en) Method of treating hyperproliferative vascular disease
US5527814A (en) Use of 2-amino-6-(trifluoromethoxy)benzothiazole for obtaining a medicament for the treatment of amyotrophic lateral sclerosis
US5624945A (en) Use of riluzole for the treatment of neuro-aids
SK282403B6 (sk) 2,4-Disulfonyl-alfa-fenyl-terc-butylnitrón alebo jeho farmaceuticky prijateľná soľ, farmaceutický prostriedok s ich obsahom a ich použitie
AU2008201179A1 (en) Method of treating of demyelinating diseases or conditions
BRPI0620985A2 (pt) composição farmacêutica contendo derivados de triazina e sensibilizadores de insulina, uso de ditos compostos e kit
HU216194B (hu) Eljárás hatóanyagként N-(4-trifluor-metil-fenil)-karboxamid-származékokat tartalmazó pszoriázis kezelésére alkalmas gyógyszerkészítmények előállítására
US5344829A (en) Use of OB-101 to treat inflammation
JPS62246515A (ja) タモキシフエン又はその製薬上認容性塩を含有する乾癬の治療剤
NZ228894A (en) 4-quinoline carboxylic acid-containing pharmaceutical compositions
JP2009535410A (ja) ピロロキノリンキノンおよびその使用
Mihich et al. Pharmacology of methylglyoxal-bis (guanylhydrazone)(CH3-G) I. Toxic and pathologic effects
JP4542777B2 (ja) 肺高血圧症を予防または治療するのに用いられる医薬の製造のためのイルベサルタンの使用
US20030216438A1 (en) Antimicrobial agent
HUT70749A (en) Anti-allergic pharmaceutical composition containing suplatast-tosilate for ophthalmic topical administracion and process for producing them
KR0133555B1 (ko) 5-플루오로우라실계 화합물에 기인한 염증의 발생을 억제할 수 있는 비-주사제 형태의 항암조성물
US20040142929A1 (en) Derivatives of aryl (or heteroaryl) azolylcarbinoles for the treatment of urinary incontinence
JP2003531113A (ja) 皮脂腺障害のためのコレステロールエステルとワックスエステルの合成の二重阻害剤
US6872751B2 (en) Composition and method for augmenting or restoring the production of fetal protein in patient in need thereof
US20040014681A1 (en) Method for treating dermatoses and tissue damage
US20080014258A1 (en) Use of fosfluridine tidoxil (FT) for the treatment of intraepithelial proliferative diseases
US3462534A (en) Production of an antidepressant effect with esters of gallic acid
NZ235100A (en) Treatment of addiction using sertraline
FR2711526A1 (fr) Utilisation de l'Acriflavine comme agent anti herpès et anti zona.
Ganesan et al. Polyphloretin phosphate temporarily potentiates prostaglandin E2 on the rat fundus, probably by inhibiting PG15-hydroxydehydrogenase

Legal Events

Date Code Title Description
HPC4 Succession in title of patentee

Owner name: AVENTIS PHARMA DEUTSCHLAND GMBH, DE